STOCK TITAN
  1. Home
  2. News
  3. OGN

Organon & Co. - OGN STOCK NEWS

Welcome to our dedicated news page for Organon & Co. (Ticker: OGN), a resource for investors and traders seeking the latest updates and insights on Organon & Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Organon & Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Organon & Co.'s position in the market.

News
Organon Reports Results for the Third Quarter Ended September 30, 2023
Rhea-AI Summary
Organon (NYSE: OGN) reported third quarter 2023 revenue of $1,519 million, with diluted earnings per share of $0.23 and non-GAAP adjusted diluted earnings per share of $0.87. The company's adjusted EBITDA was $447 million. The board of directors declared a quarterly dividend of $0.28 per share. Full year 2023 financial guidance ranges were updated, with narrowed and lowered revenue range of $6.15 billion to $6.25 billion and narrowed and lowered adjusted EBITDA margin range of 30.5% to 31.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.51%
Tags
earnings
-
News
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as Prescribed
Rhea-AI Summary
Organon and Sempre Health have formed a strategic partnership to improve medication adherence through a pricing program. Eligible patients who refill their prescriptions on time for Dulera and Asmanex will receive discounts on their medications. The program aims to address the high costs and complexity of medication regimens that contribute to non-adherence. Technology integrations and personalized text message engagement will support patients in managing their health and saving money.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
-
News
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023
Rhea-AI Summary
Organon to release Q3 2023 financial results on November 2, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
conferences earnings
News
Organon Recognized on Fortune’s 2023 Change the World List for Leadership in Expanding Access to Contraceptive Choice
Rhea-AI Summary
Organon (NYSE: OGN) named to Fortune's 2023 Change the World list for its leadership in women's health. Her Promise Access Initiative prevented 57 million unplanned pregnancies. Goal: prevent 120 million by 2030. Positive impact on social health. Access to contraception and education addressed. Increasing access globally through partnerships and investments. Established Her Plan is Her Power initiative with $30 million. Programs running in 8 countries. Global grants program. ESG strategy and goals available for download.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.83%
Tags
none
-
News
First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology
Rhea-AI Summary
Organon's JADA System effectively controls postpartum uterine bleeding, according to the RUBY study published in Obstetrics & Gynecology. The study showed a success rate of 92.5% in vaginal births and 83.7% in cesarean births. Lower blood loss prior to device insertion was associated with lower severe maternal morbidity. Adverse events in the study were consistent with expectations for managing an obstetric emergency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.26%
Tags
none
-
News
Organon Bolsters Research & Development Expertise with Two Leadership Appointments
Rhea-AI Summary
Organon appoints Juan Camilo Arjona Ferreira as CMO and Charlotte Owens as Head of Medical Affairs and Outcomes Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.15%
Tags
none
News
Organon Reports Results for the Second Quarter Ended June 30, 2023
Rhea-AI Summary
Organon (NYSE: OGN) reported second quarter 2023 revenue of $1,608 million, with diluted earnings per share of $0.95 and non-GAAP Adjusted diluted earnings per share of $1.31. The company also declared a quarterly dividend of $0.28 per share and updated its full year 2023 financial guidance ranges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.04%
Tags
earnings
-
News
Organon To Report Second Quarter Results and Host Conference Call on August 8, 2023
Rhea-AI Summary
Organon (NYSE: OGN) to release Q2 2023 financial results on August 8, 2023. Interested parties can access the live call via webcast on the Organon website. Institutional investors and analysts must pre-register to participate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences earnings
-
News
REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
News
Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock OGN logo
Organon & Co.

NYSE:OGN

OGN Rankings

#1231 Ranked by Market Cap
#4448 Ranked by Stock Gains
#479 Ranked by Dividends

OGN Stock Data

4.46B
254.87M
0.14%
79.96%
4.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Kenilworth

About OGN

organon is a dutch pharmaceutical company started in oss the netherlands. it is famous for "the pil" a birthcontrol pil. organon grew as a company and was taken over by schering plough and later on by merck and continues as msd in the netherlands. in the old days the compant was great, it used to be "gezellig" !